Table 1 Clinical characteristics of patients (n = 16)
From: Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19
Male | 11 (68.8%) |
Median age, years (IQR) | 55 (40.5–71.5) |
Median duration from onset of symptoms to hospitalization, days (IQR) | 7 (3.25–9) |
Underlying disease | |
 Diabetes mellitus | 4 (25%) |
 Hypertension | 2 (12.5%) |
 Heart disease | 2 (12.5%) |
Treatment | |
 Azithromycin | 11 (68.8%) |
 Favipiravir | 11 (68.8%) |
 Nafamostat | 12 (75%) |
 Tocilizumab | 7 (43.7%) |
Disease severity | |
 Mild | 6 (37.5%) |
 Severe | 10 (62.5%) |
PaO2/FiO2 ratio | |
 > 350 | 6 (37.5%) |
 200–300 | 5 (31.25%) |
 150–200 | 3 (18.75%) |
 < 150 | 2 (12.5%) |